Sumitomo Dainippon Pharma Annual Report 2017
49/102

Sumitomo Dainippon Pharma formulates its business continuity plan (BCP) from the viewpoint of stable supply of the pharmaceutical products that is our social mission, and assumes the occurrence of a large-scale disaster and an infectious disease pandemic, such as new strains of influenza.For example, in the outbreak of a pandemic, we respond with reference to the epidemic phase of WHO and Japan’s Ministry of Health, Labour and Welfare to establish our own epidemic danger period phases, implement countermeasures, and prepare manuals for the set up and operational procedures of a headquarters for countermeasures.Sumitomo Dainippon Pharma performs appropriate, fair and timely disclosure of information to society. We also manage information appropriately, having established a global policy for management of recording and information and various regulations on information security.With regard to personal information and Individual Numbers, the Company has established an internal Personal Information and Personal Identity Number Protection Policy and strives to safeguard this information. Additionally, internal information is appropriately managed and addressed by rules the Company has established in order to handle internal information and preempt insider trading.Furthermore, the Company works to develop and operate controls that comply with ISO 27001, the international standard on information security. Sumitomo Dainippon Pharma has been striving to align the level of rules on information security in our group companies in Japan, the U.S., Europe, and China. In parallel with this, we are engaged in activities to strengthen measures, including carrying out monitoring to confirm and assess the status of information security efforts.Business Continuity Plan (BCP)Information ManagementRisk Management SystemExecutive officer in chargeof business activity risksPresidentGroup-wide risksBusiness activity risks• Illegal transactions• Expense fraud• Illegal appropriation/usage of trade secrets• Non-compliance with local laws, regulations, etc.• Unexpected adverse reactions• Product liability incidents (PL)• Leaks of employee personal information• Illegal access• Leaks of confidential informationCrises• Earthquakes• Typhoons, torrential rain, floods• Riots, terror attacks• Communicable diseases, infectious diseases• Incidents, accidentsOthers• Inventory management, procurement• Production management• Workforce surplus/shortfall, employee turnover• IR, PR response• Intellectual property right infringement• Capital managementExecutive officer incharge of complianceGlobal RegulatoryCompliance HeadExecutive officer in chargeof information management48Sumitomo Dainippon Pharma Co., Ltd. Annual Report 2017

元のページ  ../index.html#49

このブックを見る